Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials

By afschroeder • October 22, 2025

Mayo T, Silverberg JI, Armstrong A, Guttman-Yassky E, Blauvelt A, Esdaile B, Kabashima K, Gooderham M, Kircik L, Schneider S, Bennike N, von Eyben R, Martel BC, Røpke MA, Katoh N, Alexis AF. Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials. Am J Clin Dermatol. 2025 Oct 21. doi: 10.1007/s40257-025-00985-1. Epub ahead of print. PMID: 41118053.

Tags: Dermatology, Publications

52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study

Paller AS, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H,[...]

Consistency of skin clearance with icotrokinra across patient subgroups with plaque psoriasis

Gold LS, Armstrong AW, Vender RB, Soung J, Pink AE, Cafone J, Edem BE, Reyes-Servin O, Jiang J, Cresswell K, DeKlotz CMC, Miller-Kassamali M, Yang[...]

Real-World Patient and Disease Characteristics, Treatment Outcomes and Satisfaction in Psoriasis: A Cross-Sectional and Retrospective Comparison of Advanced Therapies and Severities

Stein Gold L, Sofen HL, Siu K, Syeed S, Edson-Heredia E, Mitchell B, Goddard E, Kranz B, Gillespie-Akar L, Armstrong AW. Real-World Patient and Disease[...]